Modeling EBV infection and pathogenesis in New-generation humanized mice

Experimental and Molecular Medicine

Volumn 47, Issue 1, 2015, Pages

  Fujiwara, Shigeyoshi ^a,b   Imadome, Ken Ichi ^a   Takei, Masami ^b  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS VACCINE;

ADAPTIVE IMMUNITY; B CELL LYMPHOPROLIFERATIVE DISEASE; B LYMPHOCYTE; DISEASE MODEL; EPSTEIN BARR VIRUS ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; EPSTEIN BARR VIRUS INFECTION; EROSIVE ARTHRITIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TUMOR XENOGRAFT; ANIMAL; COMPLICATION; EPSTEIN BARR VIRUS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; VIROLOGY; XENOGRAFT;

HUMAN HERPESVIRUS 4; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HETEROGRAFTS; HUMANS; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, SCID; T-LYMPHOCYTES;

EID: 84928009043     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.88     Document Type: Review

References (58)

1. Shope T, Dechairo D, Miller G. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci USA 1973;70:2487-2491.
2. Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985;318:287-289.
3. Epstein MA, zur Hausen H, Ball G, Rabin H. Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). III. Serological and biochemical findings in an animal with reticuloproliferative disease. Int J Cancer 1975;15:17-22.
4. Johannessen I, Crawford DH. In vivo models for Epstein-Barr virus (EBV) - associated B cell lymphoproliferative disease (BLPD). Rev Med Virol 1999;9:263-277.
5. Takashima K, Ohashi M, Kitamura Y, Ando K, Nagashima K, Sugihara H et al. A new animal model for primary and persistent Epstein-Barr virus infection: human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis. J Med Virol 2008;80:455-466.
6. Rajcani J, Szenthe K, Durmanova V, Toth A, Asvanyi B, Pitlik E et al. Epstein-Barr virus (HHV-4) inoculation to rabbits by intranasal and oral routes results in subacute and/or persistent infection dissimilar to human disease. Intervirology 2014;57:254-269.
7. Okuno K, Takashima K, Kanai K, Ohashi M, Hyuga R, Sugihara H et al. Epstein-Barr virus can infect rabbits by the intranasal or peroral route: an animal model for natural primary EBV infection in humans. J Med Virol 2010;82:977-986.
8. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science 1997;276:2030-2033.
9. Wang F. Nonhuman primate models for Epstein-Barr virus infection. Curr Opin Virol 2013;3:233-237.
10. Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM et al. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathogen 2011;7:e1002308.
11. Blaskovic D, Stancekova M, Svobodova J, Mistrikova J. Isolation of five strains of herpesviruses from two species of free living small rodents. Acta Virol 1980;24:468.
12. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011;29:351-397.
13. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335:256-259.
14. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-530.
15. Fujiwara S, Matsuda G, Imadome K. Humanized mouse models of Epstein-Barr virus infection and associated diseases. Pathogens 2013;2:153-176.
16. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/gamma (c) (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-3182.
17. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304:104-107.
18. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain (null) mice. Blood 2005;106:1565-1573.
19. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012;12:786-798.
20. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013;435:14-28.
21. Leung C, Chijioke O, Gujer C, Chatterjee B, Antsiferova O, Landtwing V et al. Infectious diseases in humanized mice. Eur J Immunol 2013;43:2246-2254.
22. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006;12:1316-1322.
23. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008;198:673-682.
24. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 2009;206:1423-1434.
25. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011;85:165-177.
26. Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y et al. An Epstein-Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 2012;86:7976-7987.
27. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 2012;122:1487-1502.
28. Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P et al. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol 2004;78:13891-13900.
29. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathogen 2010;6:e1001063.
30. Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR et al. A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathogen 2011;7:e1001294.
31. Wahl A, Linnstaedt SD, Esoda C, Krisko JF, Martinez-Torres F, Delecluse HJ et al. A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. J Virol 2013;87:5437-5446.
32. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131.
33. Kikuta H, Sakiyama Y, Matsumoto S, Oh-Ishi T, Nakano T, Nagashima T et al. Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood 1993;82:3259-3264.
34. Kawaguchi H, Miyashita T, Herbst H, Niedobitek G, Asada M, Tsuchida M et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virusassociated hemophagocytic syndrome. J Clin Invest 1993;92:1444-1450.
35. Yang X, Wada T, Imadome K, Nishida N, Mukai T, Fujiwara M et al. Characterization of Epstein-Barr virus (EBV)-infected cells in EBVassociated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae 2012;3:1.
36. Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, Matsuoka M et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 2011;117:5663-5673.
37. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-2219.
38. Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine 2007;74:418-426.
39. Takei M, Mitamura K, Fujiwara S, Horie T, Ryu J, Osaka S et al. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol 1997;9:739-743.
40. Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1218-1225.
41. Kuwana Y, Takei M, Yajima M, Imadome K, Inomata H, Shiozaki M et al. Epstein-Barr virus induces erosive arthritis in humanized mice. PLoS One 2011;6:e26630.
42. Niller HH, Wolf H, Ay E, Minarovits J. Epigenetic dysregulation of Epstein-Barr virus latency and development of autoimmune disease. Adv Exp Med Biol 2011;711:82-102.
43. Heuts F, Rottenberg ME, Salamon D, Rasul E, Adori M, Klein G et al. T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J Virol 2014;88:3235-3245.
44. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006;108:487-492.
45. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007;204:705-714.
46. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009;83:7305-7321.
47. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H et al. T cell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis 2009;200:1611-1615.
48. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007;25:587-617.
49. Watanabe Y, Takahashi T, Okajima A, Shiokawa M, Ishii N, Katano I et al. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac (null) (NOG) mice (hu-HSC NOG mice). Int Immunol 2009;21:843-858.
50. Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma (null) humanized mice. Proc Natl Acad Sci USA 2010;107:13022-13027.
51. Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol 2013;132:515-525 quiz 526.
52. Chijioke O, Muller A, Feederle R, Barros MH, Krieg C, Emmel V et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep 2013;5:1489-1498.
53. Leung CS, Maurer MA, Meixlsperger S, Lippmann A, Cheong C, Zuo J et al. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 2013;121:1584-1594.
54. Meixlsperger S, Leung CS, Ramer PC, Pack M, Vanoaica LD, Breton G et al. CD141+ dendritic cells produce prominent amounts of IFN-alpha after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013;121:5034-5044.
55. Imadome K, Yajima M, Arai A, Nakazawa A, Kawano F, Ichikawa S et al. Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathogen 2011;7:e1002326.
56. Murata T, Iwata S, Siddiquey MN, Kanazawa T, Goshima F, Kawashima D et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS One 2013;8:e63566.
57. Siddiquey MN, Nakagawa H, Iwata S, Kanazawa T, Suzuki M, Imadome K et al. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. Cancer Sci 2014;105:713-722.
58. Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA et al. Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol 2013;31:635-674.